Cosette Pharmaceuticals Expands Branded Portfolio through Acquisition of SYMPAZAN(R) and Additional Products from Assertio

Cosette Pharmaceuticals, Inc., a U.S.-based, branded specialty pharmaceutical company, announced today the closing of a definitive agreement to acquire the U.S. sales and distribution rights for a ...

Assertio to Be Acquired by Garda in Cash Deal

Detailed price information for Assertio Therapeutics Inc (ASRT-Q) from The Globe and Mail including charting and trades.
PharmiWeb

Assertio Announces Agreement to be Acquired by Garda Therapeutics

Plus Contingent Value RightTender Offer Price Represents 34.6% Premium to Unaffected Price and 46.6% Premium to Unaffected 30-day Volume-Weighted Average PriceTransaction Follows Comprehensive ...
Investing

Cosette acquires seven branded drugs from Assertio for $48.9M

The transaction also includes six other branded products: INDOCIN (indomethacin) oral suspension and suppositories, SPRIX (ketorolac tromethamine) nasal spray, ZIPSOR (diclofenac potassium) ...
Investing

Assertio agrees to $125.1M sale to Garda Therapeutics

In connection with the Garda agreement, Assertio sold its Indocin, Sympazan, Sprix, Cambia, Zipsor, and Otrexup assets to Cosette Pharmaceuticals for $35 million upfront plus earnouts. These proceeds ...
Hoodline

Lake Forest Drugmaker Assertio Snapped Up In $125 Million Private Takeover Play

Lake Forest-based Assertio has struck a deal to go private, agreeing on Wednesday to be bought for $18 a share in a transaction that values the company at roughly $125 million. Wrapped into the ...
Barron's

Assertio Holdings Inc.

Assertio Holdings, Inc. is a commercial pharmaceutical company, which engages in acquisitions, licensing, and mergers. The firm focuses on portfolio of neurology, inflammation, and pain medications.